抗HMGCR免疫介导坏死性肌病的发病率:一项澳大利亚与英国回顾性多中心队列研究
该回顾性多中心队列研究在曼彻斯特、布里斯托、西澳大利亚和南澳大利亚四个独立队列中,纳入2018至2023年符合ENMC标准的109例抗HMGCR免疫介导坏死性肌病成人患者,计算年均发病率为2.9例/百万人年,他汀使用者中英国为20.4例/百万他汀使用者/年、西澳/南澳为24.1例/百万他汀使用者/年,并描述了他汀初治患者的独特表型及疾病的难治性。
要点
- 抗HMGCR免疫介导坏死性肌病年均发病率为2.9例/百万人年,他汀使用者中英国为20.4例/百万他汀使用者/年、西澳/南澳为24.1例/百万他汀使用者/年。
- 109例中101例有他汀暴露,最常见为阿托伐他汀(77/101,76.2%),诊断前他汀使用中位时长3年(范围1个月至23年)。
- 8例(7.5%)为他汀初治患者,较他汀暴露者更年轻(中位46.1岁 vs 67岁,P=0.02),非白人比例更高(5/8 vs 20/77,P=0.04),吞咽困难更常见(4/8 vs 14/94,P=0.03)。
核心结论
- 研究首次利用大型跨国队列计算了抗HMGCR免疫介导坏死性肌病的发病率,并强调该病的难治性,同时描述了他汀初治患者的独特表型及自限性肌病的罕见发生。
研究设计与样本
- 回顾性多中心队列研究,纳入曼彻斯特(英国)、布里斯托(英国)、西澳大利亚(澳大利亚)和南澳大利亚(澳大利亚)四个独立队列中2018至2023年符合ENMC标准的109例抗HMGCR免疫介导坏死性肌病成人患者(≥18岁)。
- 英国全国抗HMGCR检测由牛津大学医院实验室完成,西澳/南澳检测由PathWest实验室完成。
主要发现
- 共识别109例抗HMGCR免疫介导坏死性肌病病例,女性占51%,中位年龄66岁(IQR 58-72.2),中位随访2.3年(IQR 1.5-4.2)。
- 年均发病率为2.9例/百万人年;他汀使用者中发病率为英国20.4例/百万他汀使用者/年、西澳/南澳24.1例/百万他汀使用者/年。
- 101例有他汀暴露,最常见为阿托伐他汀(77/101,76.2%),诊断前他汀使用中位时长3年(范围1个月至23年)。
- 8例(7.5%)为他汀初治患者,较他汀暴露者更年轻(中位46.1岁 vs 67岁,P=0.02),非白人比例更高(5/8 vs 20/77,P=0.04),吞咽困难更常见(4/8 vs 14/94,P=0.03)。
- 中位峰值肌酸激酶为7020 IU/l(范围964-39076),48/105(45.7%)接受静脉注射免疫球蛋白;随访时肌酸激酶正常者50/105(47.6%),肌力正常者48/104(46.2%)。
关键数值与推荐
- 抗HMGCR免疫介导坏死性肌病诊断采用ENMC标准(2018-2023年)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immune-mediated necrotizing myopathy (IMNM) with autoantibodies targeting 3-hydroxy-3-methylglutaryl-CoA reductase (anti-HMGCR) is considered a rare complication of statin therapy. We calculate the incidence of anti-HMGCR IMNM and describe clinical characteristics in four independent cohorts: Manchester (UK), Bristol (UK), Western Australia (WA, Australia) and South Australia (SA, Australia). METHODS: Adults (≥18 years) with anti-HMGCR IMNM (ENMC criteria; 2018-2023) were identified from myositis clinic and laboratory records. Nationwide UK anti-HMGCR testing was performed at Oxford University Hospital Laboratories and state-based WA/SA testing at PathWest Laboratories. RESULTS: One hundred and nine anti-HMGCR IMNM cases were identified (51% female, median 66 years [IQR 58-72.2]) with median follow-up 2.3 years [IQR 1.5-4.2]. Mean annual incidence was 2.9 cases/million person-years. In statin users, incidence was 20.4 (UK) and 24.1 (WA/SA) cases/million statin-users/year. One hundred and one patients were statin-exposed, mostly atorvastatin (77/101, 76.2%). Median statin duration before diagnosis was 3 years (range: 1 month-23 years). Eight (7.5%) were statin-naïve and, compared with statin-exposed patients, younger (median 46.1 vs 67 years, P = 0.02), frequently of non-white ethnicity (5/8 vs 20/77, P = 0.04) and more commonly had dysphagia (4/8 vs 14/94, P = 0.03). The median peak creatine kinase (CK) was 7020 IU/l (range: 964-39076), and 48/105 (45.7%) received intravenous immunoglobulin. At follow-up, less than half had normal CK (50/105 [47.6%]) or muscle power (48/104 [46.2%]). CONCLUSION: For the first time, we have calculated an incidence of anti-HMGCR IMNM using a large, multinational cohort. We highlight the refractory nature of anti-HMGCR IMNM. We also describe the unique phenotype of statin-naïve anti-HMGCR IMNM, and the rare occurrence of self-limiting myopathy.
引用
- Khoo T, Tan E, Limaye V, et al. The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. Rheumatology (Oxford). 2025. PMID: 40347460. doi:10.1093/rheumatology/keaf238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。